Discontinue immediately if allergic or anaphylactic type reactions is suspected. Not to be inj intravascularly. Not to exceed 20 mL/hr infusion rate. Arterial & venous thromboembolic events eg, MI, stroke, DVT & pulmonary embolism; preexisting risk factors for thrombotic events eg, in-dwelling vascular catheters, history of vascular disease or thrombotic episodes; CV risk factors eg, history of atherosclerosis &/or impaired cardiac output; acquired or inherited hypercoagulable states, prolonged periods of immobilization, severe hypovolemia, diseases increasing blood viscosity, advanced age, oestrogen use; aseptic meningitis syndrome. Patients w/ anti-IgA Ab, 1st time receiving human normal Ig therapy, or when human normal Ig is switched or long interval since previous infusion. Ensure adequate hydration prior to infusion. Possibility of transmitting infective agents. May interfere w/ serological testing. Pregnancy & lactation. Paed <18 yr.
Sign Out
